@Coiltubing
BERGENBIO TO PRESENT UPDATES FROM ONGOING PHASE II BEMCENTINIB COMBINATION STUDY IN REFRACTORY NSCLC AT WCLC 2020
13.01.2021
Share This Post
· Bemcentinib in combination with pembrolizumab was well-tolerated and showed promising clinical activity in refractory lung cancer
· Updated interim data will be presented on second line patients following CPI monotherapy
Bergen, Norway, 13 January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will present an update from its Phase II study of bemcentinib in combination with anti-PD-1 therapy pembrolizumab (BGBC008) in refractory non-small cell lung cancer (NSCLC) patients at an oral presentation at the 2020 World Conference on Lung Cancer Singapore (WCLC).
BGBC008 is a Phase II single-arm, two stage study with bemcentinib and
pembrolizumab for previously treated Stage IV NSCLC patients, comprising three cohorts; chemotherapy failed patients not treated with immunotherapies (post-chemo), patients progressing on prior checkpoint inhibitor therapy (post-CPI monotherapy) and platinum-doublet chemotherapy in combination with immunotherapy (post-chemo-CPI).
The primary endpoint of the study was Overall Response Rate with pre-defined criteria to proceed from the first to second stage in each cohort. Secondary endpoints included Disease Control Rate, Progression Free Survival, Overall Survival and safety.
The interim data shows that bemcentinib in combination with pembrolizumab was well-tolerated and shows promising clinical activity in refractory lung cancer. The presentation will provide updated data from Cohort B of the study, assessing the safety and efficacy of bemcentinib in combination with anti-PD-1 therapy pembrolizumab, in refractory NSCLC patients previously treated with a PD-L1 or PD-1 checkpoint inhibitor (CPI) as a monotherapy.
The full abstract can be found on the WCLC website.
Title: A phase II study of the oral selective AXL inhibitor bemcentinib with
pembrolizumab in refractory patients with advanced NSCLC
Presenting Author: Dr. Matthew G. Krebs PhD.
Session/Abstract ID: Immunotherapy (Phase II/III Trials) / # 3647
Date/Time: Friday 29[th] January 2021 at 09.50 Singapore Time / 02.50 CET
The presentation will be available on BerGenBio’s website from 29 January
2021.
Men har mine tvil i at det vil skje pga. den salgsviljen vi har sett i dag og i går. Men igjen, biotech er som alltid case-styrt. Er resultatene så bra at man ser grunnlaget for et fase 3 studie vil det være 0 de negative kan gjøre for å holde kursen nede.
